左丙氧芬 | 2338-37-6

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 左丙氧芬
• 英文名称: α-(-)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxy-butan, l-Propoxyphen
• 英文别名: levopropoxyphene；l-propoxyphene；(2R,3S)-4-dimethylamino-3-methyl-1,2-diphenyl-2-propionyloxy-butane；(2R,3S)-4-Dimethylamino-3-methyl-1,2-diphenyl-2-propionyloxy-butan；(-)-Propoxyphen；[(2R,3S)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
• CAS: 2338-37-6
• 化学式: C₂₂H₂₉NO₂
• 分子量: 339.478
• InChiKey: XLMALTXPSGQGBX-PGRDOPGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

ADMET

代谢

在人中，主要的代谢途径是N-去甲基化，生成去甲丙氧酚...

IN MAN, MAJOR ROUTE OF METAB IS N-DEMETHYLATION TO YIELD NORPROPOXYPHENE...

来源:Hazardous Substances Data Bank (HSDB)

代谢

研究表明，在给予适当形式的(14)C-丙氧芬后，通过N-脱烷基化和脱酯化，丙氧芬发生了生物转化。

STUDIES OF (14)C-CO2 EXCRETION AFTER ADMIN OF APPROPRIATE (14)C-FORMS OF PROPOXYPHENE SHOWED THAT PROPOXYPHENE WAS BIOTRANSFORMED BY N-DEALKYLATION & DE-ESTERIFICATION. /PROPOXYPHENE/

来源:Hazardous Substances Data Bank (HSDB)

代谢

在猪体内产生3-二甲基氨基-1,2-二苯基-2-丁基丙酸酯-N-氧化物：Kadlubar FF等，生物化学与生物物理研究通讯(54) 1255, 1973年；在大鼠体内产生3-甲基氨基-1,2-二苯基-2-丁基丙酸酯：McMahon RE，药物化学杂志(14) 67, 1961年。/来自表格的丙氧芬/

YIELDS 3-DIMETHYLAMINO-1,2-DIPHENYL-2-BUTYL PROPIONATE-N-OXIDE IN PIG: KADLUBAR FF ET AL, BIOCHEM BIOPHYS RES COMMUN (54) 1255, 1973; & 3-METHYLAMINO-1,2-DIPHENYL-2-BUTYL PROPIONATE IN RAT: MCMAHON RE, J MED PHARM CHEM 84) 67, 1961. /PROPOXYPHENE, FROM TABLE/

来源:Hazardous Substances Data Bank (HSDB)

代谢

去甲丙氧芬的浓度表明，母药L-丙氧酚萘磺酸盐在血浆中浓度的差异并非由代谢转化速率的差异造成，而是由于肝脏首次通过效应的修饰所致。

CONCN OF NORPROPOXYPHENE INDICATED THAT DIFFERENCES IN PLASMA CONCN OF PARENT DRUG, L-PROPOXYPHENE NAPSYLATE, ARE NOT THE RESULT OF DIFFERENCES IN RATE OF METABOLIC CONVERSION, BUT RATHER TO A MODIFICATION OF THE FIRST PASS EFFECT IN LIVER.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

口服D-丙氧芬产生的镇痛效果可以通过预先负荷L-丙氧芬来增强。

THE ANALGESIA PRODUCED BY ORAL ADMIN OF D-PROPOXYPHENE IS ENHANCED BY INITIAL LOADING WITH L-PROPOXYPHENE.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

不良影响通常是轻微的；报告了头痛、头晕、皮疹、口干、恶心和呕吐、尿急和颤抖。/纳普西酸盐/

UNTOWARD EFFECTS ARE USUALLY MILD; HEADACHE, LIGHT-HEADINESS, SKIN RASH, DRYNESS OF MOUTH, NAUSEA & VOMITING, URINARY URGENCY, & TREMORS HAVE BEEN REPORTED. /NAPSYLATE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 人类毒性摘录

LEVOPROPOXYPHENE的副作用包括...荨麻疹、嗜睡...和眩晕。/纳普西盐/

SIDE EFFECTS OF LEVOPROPOXYPHENE INCL...URTICARIA, DROWSINESS...& DIZZINESS. /NAPSYLATE/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 非人类毒性摘录

L-PROPOXYPHENE-HCL (225 MG/KG, SC) 在小鼠大脑中降低去甲肾上腺素水平。

L-PROPOXYPHENE-HCL (225 MG/KG, SC) DECREASED NORADRENALINE LEVELS IN BRAINS OF MICE.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

口服剂量的(14)C-丙氧芬在大鼠体内被完全且迅速吸收和排泄。80%通过胆汁排泄，20%通过尿液排泄，在四天内动物体内残留的不到1%。...胆汁排泄...在狗中似乎是一个重要的排泄途径，但在人类中则不那么重要。血液中...代谢产物的水平在所有物种中都有所延长。

ORAL DOSE OF (14)C-PROPOXYPHENE WAS COMPLETELY & RAPIDLY ABSORBED & EXCRETED IN RAT. 80% WAS EXCRETED IN BILE, 20% IN URINE, & LESS THAN 1% REMAINED IN ANIMALS AFTER 4 DAYS. ... BILIARY EXCRETION...APPEARED TO BE IMPORTANT EXCRETORY ROUTE IN DOG BUT LESS SO IN MAN. BLOOD LEVELS OF...METAB WERE PROLONGED IN ALL SPECIES.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

最大L-丙氧酚-HCL浓度（口服130毫克）在无肾患者中较高（177 ng/ml 对 81 ng/ml），并且在12小时内浓度-时间曲线下的面积也更大（4310 ng·hr/ml 对 2250 ng·hr/ml），与正常受试者相比。即使在按体重标准化后，差异仍然具有统计学意义。

MAX L-PROPOXYPHENE-HCL CONCN (130 MG ORALLY) WERE HIGHER (177 VS 81 NG/ML) & AREAS UNDER CONCN-TIME CURVE OVER 12 HR WERE LARGER (4310 VS 2250 NG HR/ML) IN ANEPHRIC PT THAN IN NORMAL SUBJECTS. DIFFERENCES STATISTICALLY SIGNIFICANT EVEN AFTER NORMALIZATION FOR BODY WT.

来源:Hazardous Substances Data Bank (HSDB)

吸收、分配和排泄

肾功能不全患者的L-普罗帕酮-HCL活性代谢物，去甲普罗帕酮的血浆浓度比正常受试者更高且更持久。

PLASMA CONCN OF L-PROPOXYPHENE-HCL ACTIVE METAB, NORPROPOXYPHENE, WERE HIGHER & MORE PERSISTENT IN ANEPHRIC PT THAN NORMAL SUBJECTS.

来源:Hazardous Substances Data Bank (HSDB)

反应信息

• 作为反应物：
  描述：

  左丙氧芬 在 盐酸 作用下， 生成 (+)-4-Dimetylamino-1,2-diphenyl-3-methyl-buten
  参考文献：
  名称：

  Analgesics. The Absolute Configuration of α-(+)-4-Dimethylamino-1,2-diphenyl- 3-methyl-2-propionoxybutane, d-Propoxyphene

  摘要：

  DOI：

  10.1021/jo01044a056

文献信息

• [EN] ACRYLATE-FUNCTIONAL BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COPOLYMER FORMED THEREWITH<br/>[FR] COMPOSÉ D'ORGANOSILICIUM RAMIFIÉ À FONCTION ACRYLATE, SON PROCÉDÉ DE PRÉPARATION ET COPOLYMÈRE FORMÉ AVEC CELUI-CI
  申请人：DOW SILICONES CORP

  公开号：WO2020142474A1

  公开（公告）日：2020-07-09

  A method of preparing an acrylate-functional branched organosilicon compound ("compound") is provided, and comprises reacting (A) a branched organosilicon compound and (B) an acrylate compound in the presence of (C) a catalyst, wherein component (A) has the general formula X-Si(R1)3, where X comprises a halogen-functional moiety and each R1 is selected from R and –OSi(R4)3, with the proviso that at least one R1 is –OSi(R4)3; each R4 is selected from R, –OSi(R5)3, and –[OSiR2]mOSiR3; each R5 is selected from R, –OSi(R6)3, and –[OSiR2]mOSiR3; each R6 is selected from R and –[OSiR2]mOSiR3; each R is an independently selected hydrocarbyl group; and 0≤m≤100; with the proviso that at least one of R4, R5 and R6 is –[OSiR2]mOSiR3. The compound prepared by the method, a copolymer comprising the reaction product of the compound and a second compound, a method of forming the copolymer, and a composition comprising the copolymer are each also provided.

  提供了一种制备丙烯酸酯官能化分支有机硅化合物（“化合物”）的方法，包括在催化剂存在下，使（A）分支有机硅化合物和（B）丙烯酸酯化合物发生反应，其中组分（A）具有一般式X-Si（R1）3，其中X包括卤素官能基，每个R1从R和–OSi（R4）3中选择，但至少一个R1为–OSi（R4）3；每个R4从R、–OSi（R5）3和–[OSiR2]mOSiR3中选择；每个R5从R、–OSi（R6）3和–[OSiR2]mOSiR3中选择；每个R6从R和–[OSiR2]mOSiR3中选择；每个R是独立选择的烃基；且0≤m≤100；但至少一个R4、R5和R6为–[OSiR2]mOSiR3。还提供了通过该方法制备的化合物，包括化合物和第二化合物的反应产物的共聚物，形成共聚物的方法，以及包含共聚物的组合物。
• Technology for the Preparation of Microparticles
  申请人：Malakhov Michael

  公开号：US20090098207A1

  公开（公告）日：2009-04-16

  Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.

  微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触，并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
• [EN] BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COPOLYMER FORMED THEREWITH<br/>[FR] COMPOSÉ D'ORGANOSILICIUM RAMIFIÉ, SON PROCÉDÉ DE PRÉPARATION ET COPOLYMÈRE FORMÉ AVEC CELUI-CI
  申请人：DOW SILICONES CORP

  公开号：WO2020142370A1

  公开（公告）日：2020-07-09

  A branched organosilicon compound ("compound") having the general formula (R1)3Si- X-Y is provided. In the formula: each R1 is selected from R and -OSi(R4)3, with the proviso that at least one R1 is -OSi(R4)3; each R is independently a substituted or unsubstituted hydrocarbyl group; each R4 is selected from R, -OSi(R5)3, and -[OSiR2]mOSiR3; each R5 is selected from R, -OSi(R6)3, and -[OSiR2]mOSiR3; each R6 is selected from R and -[OSiR2]mOSiR3; with the proviso that at least one of R4, R5 and R6 is -[OSiR2]mOSiR3; 0

  提供具有一般式（R1）3Si-X-Y的分支有机硅化合物（“化合物”）。在该式中：每个R1从R和-OSi（R4）3中选择，但至少有一个R1为-OSi（R4）3；每个R都是独立的取代或未取代的烃基团；每个R4从R、-OSi（R5）3和-[OSiR2]mOSiR3中选择；每个R5从R、-OSi（R6）3和-[OSiR2]mOSiR3中选择；每个R6从R和-[OSiR2]mOSiR3中选择；但至少有一个R4、R5和R6为-[OSiR2]mOSiR3；0
• [EN] BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND RELATED COMPOSITIONS<br/>[FR] COMPOSÉ D'ORGANOSILICIUM RAMIFIÉ, PROCÉDÉ DE PRÉPARATION CORRESPONDANT ET COMPOSITIONS ASSOCIÉES
  申请人：DOW SILICONES CORP

  公开号：WO2020142380A1

  公开（公告）日：2020-07-09

  A branched organosilicon compound ("compound") having the general formula (R1)3SiX-NR2-D-Z(R7)a is provided. In the formula: each R1 is selected from R and –OSi(R4)3, with the proviso that at least one R1 is –OSi(R4)3; where each R4 is selected from R, –OSi(R5)3, and – [OSiR2]mOSiR3; where each R5 is selected from R, –OSi(R6)3, and –[OSiR2]mOSiR3; where each R6 is selected from R and –[OSiR2]mOSiR3; with the proviso that at least one of R4, R5 and R6 is –[OSiR2]mOSiR3; where each R is independently a substituted or unsubstituted hydrocarbyl group; and where 0≤m≤100; each of X and D is an independently selected divalent linking group; each R2 and R7 is an independently selected substituted or unsubstituted hydrocarbyl group or H; Z is O or N; and subscript a is the valency of Z. Also provided is a method of preparing the compound and a composition including the compound.

  提供具有一般式（R1）3SiX-NR2-D-Z（R7）a的分支有机硅化合物（“化合物”）。在公式中：每个R1从R和-OSi（R4）3中选择，条件是至少有一个R1是-OSi（R4）3；其中每个R4从R，-OSi（R5）3和-[OSiR2]mOSiR3中选择；其中每个R5从R，-OSi（R6）3和-[OSiR2]mOSiR3中选择；其中每个R6从R和-[OSiR2]mOSiR3中选择，条件是至少有一个R4，R5和R6是-[OSiR2]mOSiR3；每个R独立地是取代或未取代的烃基；且0≤m≤100；每个X和D是独立选择的二价连接基；每个R2和R7是独立选择的取代或未取代的烃基或H；Z是O或N；下标a是Z的价。还提供了一种制备该化合物的方法和包括该化合物的组合物。
• [EN] BRANCHED ORGANOSILICON COMPOUND, METHOD OF PREPARING SAME, AND COMPOSITIONS COMPRISING SAME<br/>[FR] COMPOSÉ D'ORGANOSILICIUM RAMIFIÉ, PROCÉDÉ DE PRÉPARATION DUDIT COMPOSÉ ET COMPOSITIONS COMPORTANT LEDIT COMPOSÉ
  申请人：DOW SILICONES CORP

  公开号：WO2020142444A1

  公开（公告）日：2020-07-09

  A branched organosilicon compound is provided which has the general formula (R1)3Si-X-NR2-X1 -NR22- In the formula: each R1 is selected from R and -OSi(R4)3, with the proviso that at least one R1 is -OSi(R4)3; each R4 is selected from R, -OSi(R5)3, and -[OSiR2]mOSiR3; each R1 is selected from R, -OSi(R6)3, and -[OSiR2]mOSiR3; each R6 is selected from R and -[OSiR2]mOSiR3; with the proviso that at least one of R4, R1 and R6 is -[OSiR2]mOSiR3; 0

  提供了具有通式(R1)3Si-X-NR2-X1-NR22-的分支有机硅化合物。在该式中：每个R1从R和-OSi(R4)3中选择，但至少有一个R1是-OSi(R4)3；每个R4从R、-OSi(R5)3和-[OSiR2]mOSiR3中选择；每个R1从R、-OSi(R6)3和-[OSiR2]mOSiR3中选择；每个R6从R和-[OSiR2]mOSiR3中选择；但至少有一个R4、R1和R6是-[OSiR2]mOSiR3；0

表征谱图